Completion capital for asset completion, licensing progression and first commercial production
A planning-secured, compliance-led production asset in Northern Ireland positioned for licensed UK prescription supply.
Investment case
A planning-secured, compliance-led production asset
Planning secured
The site already has granted planning permission and identified premises.
Licensed B2B route
Facility to distributor to pharmacy to patient.
Import-led market
Domestic compliant capacity remains limited while UK patient access grows.
Northern Ireland position
UK jurisdiction with a differentiated strategic location story.
Scalable site
c.17,000 sq ft initial fit-out with expansion potential to 100,000+ sq ft.
Founder aligned
Founder capital already committed, helping investors fund completion rather than concept.
Credibility signals
The project already has real groundwork behind it
Planning reference
LA03/2022/0307/F
Planning granted
24 May 2024
Founder capital invested
£401,999
Premises support
Property support and option structure already in place
Completion capital would support
Fit-out, licensing progression and commissioning
Core facility works and fit-out
Compliance, licensing and inspection readiness
Working capital and first commercial production runway
Execution path
Momentum matters
A simple timeline reassures investors that the project is already in motion.
